Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Synoptic reporting increases quality of upper gastrointestinal cancer pathology reports.

Baranov NS, Nagtegaal ID, van Grieken NCT, Verhoeven RHA, Voorham QJM, Rosman C, van der Post RS.

Virchows Arch. 2019 May 29. doi: 10.1007/s00428-019-02586-w. [Epub ahead of print]

PMID:
31144018
2.

Genome-wide cell-free DNA fragmentation in patients with cancer.

Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE.

Nature. 2019 Jun;570(7761):385-389. doi: 10.1038/s41586-019-1272-6. Epub 2019 May 29.

PMID:
31142840
3.

Narrow-Band Imaging Improves Detection of Colorectal Peritoneal Metastases: A Clinical Study Comparing Advanced Imaging Techniques.

Sluiter NR, Vlek SL, Wijsmuller AR, Brandsma HT, de Vet HCW, van Grieken NCT, Kazemier G, Tuynman JB.

Ann Surg Oncol. 2019 Jan;26(1):156-164. doi: 10.1245/s10434-018-7005-5. Epub 2018 Nov 12.

4.

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.

Smeets D, Miller IS, O'Connor DP, Das S, Moran B, Boeckx B, Gaiser T, Betge J, Barat A, Klinger R, van Grieken NCT, Cremolini C, Prenen H, Mazzone M, Depreeuw J, Bacon O, Fender B, Brady J, Hennessy BT, McNamara DA, Kay E, Verheul HM, Maarten N, Gallagher WM, Murphy V, Prehn JHM, Koopman M, Punt CJA, Loupakis F, Ebert MPA, Ylstra B, Lambrechts D, Byrne AT.

Nat Commun. 2018 Oct 5;9(1):4112. doi: 10.1038/s41467-018-06567-6.

5.

Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial.

Claassen YHM, Hartgrink HH, de Steur WO, Dikken JL, van Sandick JW, van Grieken NCT, Cats A, Trip AK, Jansen EPM, Kranenbarg WMM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH.

Gastric Cancer. 2019 Mar;22(2):369-376. doi: 10.1007/s10120-018-0875-1. Epub 2018 Sep 20.

6.

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.

Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M.

BMC Cancer. 2018 Sep 10;18(1):877. doi: 10.1186/s12885-018-4770-2.

7.

Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer.

Neerincx M, Poel D, Sie DLS, van Grieken NCT, Shankaraiah RC, van der Wolf-de Lijster FSW, van Waesberghe JTM, Burggraaf JD, Eijk PP, Verhoef C, Ylstra B, Meijer GA, van de Wiel MA, Buffart TE, Verheul HMW.

PLoS One. 2018 Aug 3;13(8):e0201809. doi: 10.1371/journal.pone.0201809. eCollection 2018.

8.

MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer.

van den Broek E, den Uil SH, Coupé VMH, Delis-van Diemen PM, Bolijn AS, Bril H, Stockmann HBAC, van Grieken NCT, Meijer GA, Fijneman RJA.

Oncotarget. 2018 Jun 29;9(50):29445-29452. doi: 10.18632/oncotarget.25655. eCollection 2018 Jun 29.

9.

Effect of Hospital Volume With Respect to Performing Gastric Cancer Resection on Recurrence and Survival: Results from the CRITICS Trial.

Claassen YHM, van Amelsfoort RM, Hartgrink HH, Dikken JL, de Steur WO, van Sandick JW, van Grieken NCT, Cats A, Boot H, Trip AK, Jansen EPM, Kranenbarg EM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH.

Ann Surg. 2018 Jul 10. doi: 10.1097/SLA.0000000000002940. [Epub ahead of print]

PMID:
29995679
10.

Consensus molecular subtype classification of colorectal adenomas.

Komor MA, Bosch LJ, Bounova G, Bolijn AS, Delis-van Diemen PM, Rausch C, Hoogstrate Y, Stubbs AP, de Jong M, Jenster G, van Grieken NC, Carvalho B, Wessels LF, Jimenez CR, Fijneman RJ, Meijer GA; NGS-ProToCol Consortium:.

J Pathol. 2018 Nov;246(3):266-276. doi: 10.1002/path.5129. Epub 2018 Aug 31.

11.

Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis.

Meijer LL, Alberga AJ, de Bakker JK, van der Vliet HJ, Le Large TYS, van Grieken NCT, de Vries R, Daams F, Zonderhuis BM, Kazemier G.

Ann Surg Oncol. 2018 Sep;25(9):2681-2692. doi: 10.1245/s10434-018-6567-6. Epub 2018 Jun 26.

12.

Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.

van Dijk E, Biesma HD, Cordes M, Smeets D, Neerincx M, Das S, Eijk PP, Murphy V, Barat A, Bacon O, Prehn JHM, Betge J, Gaiser T, Fender B, Meijer GA, McNamara DA, Klinger R, Koopman M, Ebert MPA, Kay EW, Hennessey BT, Verheul HMW, Gallagher WM, O'Connor DP, Punt CJA, Loupakis F, Lambrechts D, Byrne AT, van Grieken NCT, Ylstra B.

J Clin Oncol. 2018 Jul 10;36(20):2052-2060. doi: 10.1200/JCO.2017.77.1782. Epub 2018 May 24.

PMID:
29792754
13.

Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas.

Carvalho B, Diosdado B, Terhaar Sive Droste JS, Bolijn AS, Komor MA, de Wit M, Bosch LJW, van Burink M, Dekker E, Kuipers EJ, Coupé VMH, van Grieken NCT, Fijneman RJA, Meijer GA.

Cancer Prev Res (Phila). 2018 Jul;11(7):403-412. doi: 10.1158/1940-6207.CAPR-17-0317. Epub 2018 Apr 23.

14.

Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: a multicenter prospective study (PLASTIC-study).

Brenkman HJF, Gertsen EC, Vegt E, van Hillegersberg R, van Berge Henegouwen MI, Gisbertz SS, Luyer MDP, Nieuwenhuijzen GAP, van Lanschot JJB, Lagarde SM, de Steur WO, Hartgrink HH, Stoot JHMB, Hulsewe KWE, Spillenaar Bilgen EJ, van Det MJ, Kouwenhoven EA, van der Peet DL, Daams F, van Sandick JW, van Grieken NCT, Heisterkamp J, van Etten B, Haveman JW, Pierie JP, Jonker F, Thijssen AY, Belt EJT, van Duijvendijk P, Wassenaar E, van Laarhoven HWM, Wessels FJ, Haj Mohammad N, van Stel HF, Frederix GWJ, Siersema PD, Ruurda JP; PLASTIC Study Group.

BMC Cancer. 2018 Apr 20;18(1):450. doi: 10.1186/s12885-018-4367-9.

15.

Association between hospital volume and quality of gastric cancer surgery in the CRITICS trial.

Claassen YHM, van Sandick JW, Hartgrink HH, Dikken JL, De Steur WO, van Grieken NCT, Boot H, Cats A, Trip AK, Jansen EPM, Meershoek-Klein Kranenbarg WM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH.

Br J Surg. 2018 May;105(6):728-735. doi: 10.1002/bjs.10773.

PMID:
29652082
16.

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.

Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators.

Lancet Oncol. 2018 May;19(5):616-628. doi: 10.1016/S1470-2045(18)30132-3. Epub 2018 Apr 9.

PMID:
29650363
17.

Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial.

Claassen YHM, Hartgrink HH, Dikken JL, de Steur WO, van Sandick JW, van Grieken NCT, Cats A, Trip AK, Jansen EPM, Meershoek-Klein Kranenbarg WM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH.

Eur J Surg Oncol. 2018 May;44(5):613-619. doi: 10.1016/j.ejso.2018.02.004. Epub 2018 Feb 9.

PMID:
29503129
18.

Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer.

Bosch LJW, Trooskens G, Snaebjornsson P, Coupé VMH, Mongera S, Haan JC, Richman SD, Koopman M, Tol J, de Meyer T, Louwagie J, Dehaspe L, van Grieken NCT, Ylstra B, Verheul HMW, van Engeland M, Nagtegaal ID, Herman JG, Quirke P, Seymour MT, Punt CJA, van Criekinge W, Carvalho B, Meijer GA.

Oncotarget. 2017 Jun 27;8(38):63140-63154. doi: 10.18632/oncotarget.18702. eCollection 2017 Sep 8.

19.

Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial.

Claassen YHM, de Steur WO, Hartgrink HH, Dikken JL, van Sandick JW, van Grieken NCT, Cats A, Trip AK, Jansen EPM, Kranenbarg WMM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH.

Ann Surg. 2018 Dec;268(6):1008-1013. doi: 10.1097/SLA.0000000000002444.

PMID:
28817437
20.

Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary.

den Bakker CM, Smit JK, Bruynzeel AME, van Grieken NCT, Daams F, Derks S, Cuesta MA, Plukker JTM, van der Peet DL.

J Thorac Dis. 2017 Jul;9(Suppl 8):S843-S850. doi: 10.21037/jtd.2017.06.123.

21.

Direct detection of early-stage cancers using circulating tumor DNA.

Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA Jr, Jones S, Angiuoli S, Ørntoft T, Nielsen HJ, Andersen CL, Velculescu VE.

Sci Transl Med. 2017 Aug 16;9(403). pii: eaan2415. doi: 10.1126/scitranslmed.aan2415.

PMID:
28814544
22.

Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative.

Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, Vink GR, Berbee M, van Berge Henegouwen MI, Bloemendal HJ, Bruno MJ, Burgmans MC, Busch ORC, Coene PPLO, Coupé VMH, Dekker JWT, van Eijck CHJ, Elferink MAG, Erdkamp FLG, van Grevenstein WMU, de Groot JWB, van Grieken NCT, de Hingh IHJT, Hulshof MCCM, Ijzermans JNM, Kwakkenbos L, Lemmens VEPP, Los M, Meijer GA, Molenaar IQ, Nieuwenhuijzen GAP, de Noo ME, van de Poll-Franse LV, Punt CJA, Rietbroek RC, Roeloffzen WWH, Rozema T, Ruurda JP, van Sandick JW, Schiphorst AHW, Schipper H, Siersema PD, Slingerland M, Sommeijer DW, Spaander MCW, Sprangers MAG, Stockmann HBAC, Strijker M, van Tienhoven G, Timmermans LM, Tjin-A-Ton MLR, van der Velden AMT, Verhaar MJ, Verkooijen HM, Vles WJ, de Vos-Geelen JMPGM, Wilmink JW, Zimmerman DDE, van Oijen MGH, Koopman M, Besselink MGH, van Laarhoven HWM; Dutch Pancreatic Cancer Group, Dutch Upper GI Cancer Group and PLCRC working group.

Acta Oncol. 2018 Feb;57(2):195-202. doi: 10.1080/0284186X.2017.1346381. Epub 2017 Jul 19.

PMID:
28723307
23.

Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis.

Creemers A, Ter Veer E, de Waal L, Lodder P, Hooijer GKJ, van Grieken NCT, Bijlsma MF, Meijer SL, van Oijen MGH, van Laarhoven HWM.

Sci Rep. 2017 Jun 9;7(1):3135. doi: 10.1038/s41598-017-03304-9.

24.

Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.

Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R.

Oncotarget. 2017 Jun 27;8(26):42949-42961. doi: 10.18632/oncotarget.17306.

25.

Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years.

Snaebjornsson P, Jonasson L, Olafsdottir EJ, van Grieken NCT, Moller PH, Theodors A, Jonsson T, Meijer GA, Jonasson JG.

Int J Cancer. 2017 Aug 1;141(3):531-539. doi: 10.1002/ijc.30766. Epub 2017 May 19.

26.

Irreversible Electroporation to Treat Malignant Tumor Recurrences Within the Pelvic Cavity: A Case Series.

Vroomen LGPH, Scheffer HJ, Melenhorst MCAM, van Grieken N, van den Tol MP, Meijerink MR.

Cardiovasc Intervent Radiol. 2017 Oct;40(10):1631-1640. doi: 10.1007/s00270-017-1657-6. Epub 2017 May 3.

27.

Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection.

Labots M, van der Mijn JC, Beekhof R, Piersma SR, de Goeij-de Haas RR, Pham TV, Knol JC, Dekker H, van Grieken NCT, Verheul HMW, Jiménez CR.

J Proteomics. 2017 Jun 6;162:99-107. doi: 10.1016/j.jprot.2017.04.014. Epub 2017 Apr 23.

PMID:
28442448
28.

Outcome of Referrals for Non-Responsive Celiac Disease in a Tertiary Center: Low Incidence of Refractory Celiac Disease in the Netherlands.

van Wanrooij RL, Bouma G, Bontkes HJ, Neefjes-Borst A, van Grieken NC, von Blomberg BM, Mulder CJ.

Clin Transl Gastroenterol. 2017 Jan 26;8(1):e218. doi: 10.1038/ctg.2016.70.

29.

Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.

den Uil SH, Coupé VM, Linnekamp JF, van den Broek E, Goos JA, Delis-van Diemen PM, Belt EJ, van Grieken NC, Scott PM, Vermeulen L, Medema JP, Bril H, Stockmann HB, Cormier RT, Meijer GA, Fijneman RJ.

Br J Cancer. 2016 Dec 6;115(12):1565-1574. doi: 10.1038/bjc.2016.376. Epub 2016 Nov 17.

30.

Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.

Betge J, Barat A, Murphy V, Hielscher T, Van Grieken NC, Belle S, Zhan T, Härtel N, Kripp M, Bacon O, Cordes M, Kay EW, Verheul HM, Neerincx M, Hennessy B, Hofheinz RD, Gaiser T, Ylstra B, Prehn JH, Lambrechts D, Byrne AT, Ebert MP, Schulte N.

Digestion. 2016;94(3):129-137. doi: 10.1159/000449412. Epub 2016 Oct 19.

PMID:
27756074
31.

Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit.

Busweiler LA, Wijnhoven BP, van Berge Henegouwen MI, Henneman D, van Grieken NC, Wouters MW, van Hillegersberg R, van Sandick JW; Dutch Upper Gastrointestinal Cancer Audit (DUCA) Group.

Br J Surg. 2016 Dec;103(13):1855-1863. doi: 10.1002/bjs.10303. Epub 2016 Oct 5.

PMID:
27704530
32.

A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer.

Borstlap WA, Tanis PJ, Koedam TW, Marijnen CA, Cunningham C, Dekker E, van Leerdam ME, Meijer G, van Grieken N, Nagtegaal ID, Punt CJ, Dijkgraaf MG, De Wilt JH, Beets G, de Graaf EJ, van Geloven AA, Gerhards MF, van Westreenen HL, van de Ven AW, van Duijvendijk P, de Hingh IH, Leijtens JW, Sietses C, Spillenaar-Bilgen EJ, Vuylsteke RJ, Hoff C, Burger JW, van Grevenstein WM, Pronk A, Bosker RJ, Prins H, Smits AB, Bruin S, Zimmerman DD, Stassen LP, Dunker MS, Westerterp M, Coene PP, Stoot J, Bemelman WA, Tuynman JB.

BMC Cancer. 2016 Jul 21;16:513. doi: 10.1186/s12885-016-2557-x.

33.

MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing.

Neerincx M, Sie DL, van de Wiel MA, van Grieken NC, Burggraaf JD, Dekker H, Eijk PP, Ylstra B, Verhoef C, Meijer GA, Buffart TE, Verheul HM.

Oncogenesis. 2015 Oct 5;4:e170. doi: 10.1038/oncsis.2015.29.

34.

Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.

de Cuba EM, Snaebjornsson P, Heideman DA, van Grieken NC, Bosch LJ, Fijneman RJ, Belt E, Bril H, Stockmann HB, Hooijberg E, Punt CJ, Koopman M, Nagtegaal ID, Coupé VH, Carvalho B, Meijer GA.

Int J Cancer. 2016 Mar 1;138(5):1139-45. doi: 10.1002/ijc.29855. Epub 2015 Oct 23.

35.

Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.

van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, DeGregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJ, O'Donovan M, Oliveira C, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe ST, van Dijck B, van Grieken NC, van Hillegersberg R, van Sandick JW, Vehof R, van Krieken JH, Fitzgerald RC.

J Med Genet. 2015 Jun;52(6):361-74. doi: 10.1136/jmedgenet-2015-103094. Epub 2015 May 15. Review.

36.

Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).

Huiskens J, van Gulik TM, van Lienden KP, Engelbrecht MR, Meijer GA, van Grieken NC, Schriek J, Keijser A, Mol L, Molenaar IQ, Verhoef C, de Jong KP, Dejong KH, Kazemier G, Ruers TM, de Wilt JH, van Tinteren H, Punt CJ.

BMC Cancer. 2015 May 6;15:365. doi: 10.1186/s12885-015-1323-9.

37.

Genomic landscape of metastatic colorectal cancer.

Haan JC, Labots M, Rausch C, Koopman M, Tol J, Mekenkamp LJ, van de Wiel MA, Israeli D, van Essen HF, van Grieken NC, Voorham QJ, Bosch LJ, Qu X, Kabbarah O, Verheul HM, Nagtegaal ID, Punt CJ, Ylstra B, Meijer GA.

Nat Commun. 2014 Nov 14;5:5457. doi: 10.1038/ncomms6457.

38.

Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas.

Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P.

Gut. 2015 Nov;64(11):1721-31. doi: 10.1136/gutjnl-2014-308252. Epub 2014 Nov 10.

39.

Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.

Sie D, Snijders PJ, Meijer GA, Doeleman MW, van Moorsel MI, van Essen HF, Eijk PP, Grünberg K, van Grieken NC, Thunnissen E, Verheul HM, Smit EF, Ylstra B, Heideman DA.

Cell Oncol (Dordr). 2014 Oct;37(5):353-61. doi: 10.1007/s13402-014-0196-2. Epub 2014 Sep 11.

PMID:
25209392
40.

High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection.

Labots M, Buffart TE, Haan JC, van Grieken NC, Tijssen M, van de Velde CJ, Grabsch HI, Ylstra B, Carvalho B, Fijneman RJ, Verheul HM, Meijer GA.

Cell Oncol (Dordr). 2014 Feb;37(1):41-52. doi: 10.1007/s13402-013-0162-4. Epub 2013 Dec 31.

PMID:
24379144
41.

Promoter methylation of Wnt-antagonists in polypoid and nonpolypoid colorectal adenomas.

Voorham QJ, Janssen J, Tijssen M, Snellenberg S, Mongera S, van Grieken NC, Grabsch H, Kliment M, Rembacken BJ, Mulder CJ, van Engeland M, Meijer GA, Steenbergen RD, Carvalho B.

BMC Cancer. 2013 Dec 19;13:603. doi: 10.1186/1471-2407-13-603.

42.

pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis. Shepherd's local peritoneal involvement revisited.

Snaebjornsson P, Coupe VM, Jonasson L, Meijer GA, van Grieken NC, Jonasson JG.

Int J Cancer. 2014 Jul 15;135(2):467-78. doi: 10.1002/ijc.28676. Epub 2014 Jan 10.

43.

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study.

van Grieken NC, Aoyama T, Chambers PA, Bottomley D, Ward LC, Inam I, Buffart TE, Das K, Lim T, Pang B, Zhang SL, Tan IB, Carvalho B, Heideman DA, Miyagi Y, Kameda Y, Arai T, Meijer GA, Tsuburaya A, Tan P, Yoshikawa T, Grabsch HI.

Br J Cancer. 2013 Apr 16;108(7):1495-501. doi: 10.1038/bjc.2013.109. Epub 2013 Mar 19. Erratum in: Br J Cancer. 2014 Jan 21;110(2):546. Aoyma, T [corrected to Aoyama, T].

44.

Laparoscopic sentinel lymph node identification in patients with colon carcinoma using a near-infrared dye: description of a new technique and feasibility study.

van der Pas MH, Ankersmit M, Stockmann HB, Silvis R, van Grieken NC, Bril H, Meijerink WJ.

J Laparoendosc Adv Surg Tech A. 2013 Apr;23(4):367-71. doi: 10.1089/lap.2012.0407. Epub 2013 Mar 11.

PMID:
23477368
45.

Duodenal lymphoid nodularity in common variable immunodeficiency.

de Boer NK, van Grieken NC, van Weyenberg SJ.

Dig Liver Dis. 2013 Feb;45(2):e5. doi: 10.1016/j.dld.2012.08.013. Epub 2012 Sep 19. No abstract available.

PMID:
22999593
46.

Comprehensive mutation analysis in colorectal flat adenomas.

Voorham QJ, Carvalho B, Spiertz AJ, Claes B, Mongera S, van Grieken NC, Grabsch H, Kliment M, Rembacken B, van de Wiel MA, Quirke P, Mulder CJ, Lambrechts D, van Engeland M, Meijer GA.

PLoS One. 2012;7(7):e41963. doi: 10.1371/journal.pone.0041963. Epub 2012 Jul 27.

47.

Chromosome 5q loss in colorectal flat adenomas.

Voorham QJ, Carvalho B, Spiertz AJ, van Grieken NC, Mongera S, Rondagh EJ, van de Wiel MA, Jordanova ES, Ylstra B, Kliment M, Grabsch H, Rembacken BJ, Arai T, de Bruïne AP, Sanduleanu S, Quirke P, Mulder CJ, van Engeland M, Meijer GA.

Clin Cancer Res. 2012 Sep 1;18(17):4560-9. Epub 2012 Jul 3. Erratum in: Clin Cancer Res. 2013 May 15;19(10):2787.

48.

Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer.

Wu Y, Grabsch H, Ivanova T, Tan IB, Murray J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, Lee M, Lee J, Koo JH, Yeoh KG, van Grieken N, Ylstra B, Rha SY, Ajani JA, Cheong JH, Noh SH, Lim KH, Boussioutas A, Lee JS, Tan P.

Gut. 2013 Aug;62(8):1100-11. doi: 10.1136/gutjnl-2011-301373. Epub 2012 Jun 26.

PMID:
22735568
49.

Iron deficiency after non-small cell lung cancer. Ileal polypoid angiodysplasia.

Van Weyenberg SJ, Van Grieken NC, Van Waesberghe JH.

Gastroenterology. 2012 Jun;142(7):e3-4. doi: 10.1053/j.gastro.2011.11.050. Epub 2012 Apr 26. No abstract available.

PMID:
22542835
50.

Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer.

Buffart TE, Carvalho B, van Grieken NC, van Wieringen WN, Tijssen M, Kranenbarg EM, Verheul HM, Grabsch HI, Ylstra B, van de Velde CJ, Meijer GA.

Oncologist. 2012;17(5):653-62. doi: 10.1634/theoncologist.2010-0379. Epub 2012 Apr 24.

Supplemental Content

Loading ...
Support Center